D. Ross Camidge

63.2k total citations · 13 hit papers
539 papers, 24.2k citations indexed

About

D. Ross Camidge is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, D. Ross Camidge has authored 539 papers receiving a total of 24.2k indexed citations (citations by other indexed papers that have themselves been cited), including 428 papers in Pulmonary and Respiratory Medicine, 359 papers in Oncology and 123 papers in Molecular Biology. Recurrent topics in D. Ross Camidge's work include Lung Cancer Treatments and Mutations (406 papers), Lung Cancer Research Studies (168 papers) and Colorectal Cancer Treatments and Studies (101 papers). D. Ross Camidge is often cited by papers focused on Lung Cancer Treatments and Mutations (406 papers), Lung Cancer Research Studies (168 papers) and Colorectal Cancer Treatments and Studies (101 papers). D. Ross Camidge collaborates with scholars based in United States, South Korea and France. D. Ross Camidge's co-authors include Robert C. Doebele, Sai‐Hong Ignatius Ou, Marileila Varella‐Garcia, Alice T. Shaw, Dara L. Aisner, Benjamin Solomon, Lecia V. Sequist, Shirish M. Gadgeel, William Pao and Andrew Weickhardt and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

D. Ross Camidge

523 papers receiving 23.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

2017 1.6k citations D. Ross Camidge, Alice T. Shaw et al. profile →
Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer

2012 820 citations Robert C. Doebele, Amanda Pilling et al. Clinical Cancer Research profile →
Acquired resistance to TKIs in solid tumours: learning from lung cancer

2014 677 citations D. Ross Camidge, William Pao et al. profile →
Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer

2012 508 citations Andrew Weickhardt, Paul A. Bunn et al. Journal of Thoracic Oncology profile →
Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastases

2015 468 citations Alice T. Shaw, Gregory J. Riely et al. Journal of Clinical Oncology profile →
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial

2015 462 citations Alice T. Shaw, Gregory J. Riely et al. profile →
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial

2017 430 citations Harry J.M. Groen, Scott Gettinger et al. Journal of Clinical Oncology profile →
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study

2020 414 citations D. Ross Camidge, Rafał Dziadziuszko et al. Annals of Oncology profile →
Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC

2019 356 citations D. Ross Camidge, Robert C. Doebele et al. profile →
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study

2019 319 citations D. Ross Camidge, Rafał Dziadziuszko et al. Journal of Thoracic Oncology profile →
ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer

2019 269 citations Alice T. Shaw, Todd M. Bauer et al. Journal of Clinical Oncology profile →
Targeting MET in Lung Cancer: Will Expectations Finally Be MET?

2016 268 citations Alexander Drilon, Federico Cappuzzo et al. Journal of Thoracic Oncology profile →
Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies

2022 121 citations Egbert F. Smit, D. Ross Camidge et al. profile →

Peers

Countries citing papers authored by D. Ross Camidge

Since Specialization

Citations

This map shows the geographic impact of D. Ross Camidge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Ross Camidge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Ross Camidge more than expected).

Fields of papers citing papers by D. Ross Camidge

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Ross Camidge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Ross Camidge. The network helps show where D. Ross Camidge may publish in the future.

Co-authorship network of co-authors of D. Ross Camidge

This figure shows the co-authorship network connecting the top 25 collaborators of D. Ross Camidge. A scholar is included among the top collaborators of D. Ross Camidge based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Ross Camidge. D. Ross Camidge is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	98P: Exploratory analysis showed increased overall survival among non-small cell lung cancer (NSCLC) patients with mutated KRAS compared with wildtype KRAS in a phase II trial of mecbotamab vedotin (CAB-AXL-ADC) 2025 ·Journal of Thoracic Oncology ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Marliese Alexander, Richy Agajanian, J. Zugazagoitia, Carl M. Gay, (unknown), (unknown), (unknown), Youming Chen, (unknown), Charles Kuzma, (unknown), (unknown), Kartik Aysola, D. Ross Camidge	0
2	1256MO Phase I/II ARROS-1 study of zidesamtinib (NVL-520) in ROS1 fusion-positive solid tumours 2024 ·Annals of Oncology ·B. Besse, Alexander Drilon, BC Cho, D. Ross Camidge, Joel W. Neal, C-C. Lin, (unknown), (unknown), (unknown), Eudald Felip, Anthonie J. van der Wekken, (unknown), (unknown), (unknown), Manoj Samant, Jiayu Shen, Yun Sun, Viola W. Zhu, Vipul Upadhyay, W. Marston Linehan	6
3	1379P c-Met protein overexpression and telisotuzumab vedotin efficacy by biopsy age, type, and region in the LUMINOSITY phase II study 2024 ·Annals of Oncology ·(unknown), Shobhit Baijal, Jiebo Luo, Nan Zhang, Christine K. Ratajczak, Peter Ansell, Shaowen Lu, D. Ross Camidge	1
4	742 Phase 1/2 study of the bispecific 4–1BB and PD-L1 antibody INBRX-105 alone and in combination with pembrolizumab in select solid tumors 2023 ·SHILAP Revista de lepidopterología ·Jong Chul Park, David Berz, Manish Sharma, Erminia Massarelli, Ralph J. Hauke, Frank Tsai, David S. Hong, (unknown), Justin Call, Jennifer W. Carlisle, Rachel E. Sanborn, Naomi B. Haas, John Hamm, D. Ross Camidge, Alexander I. Spira, (unknown), (unknown), (unknown), Anthony W. Tolcher	2
5	1397P Prevalence, molecular characterization, and prognosis of MET–overexpressing non-small cell lung cancer (NSCLC) in a real-world patient cohort 2023 ·Annals of Oncology ·Jair Bar, (unknown), (unknown), Shobhit Baijal, Weidong Zhao, Alexander Liede, Leon Raskin, Athanasios Vasilopoulos, Ming Li, Lisa Roberts-Rapp, Fang Jiang, Christine K. Ratajczak, Shun Lü, Peter Ansell, D. Ross Camidge	2
6	O7-4 Phase 1b efficacy of telisotuzumab vedotin and osimertinib in Asian vs non-Asian patients with advanced NSCLC 2023 ·Annals of Oncology ·Hidehito Horinouchi, Jonathan W. Goldman, Byoung Chul Cho, Pascale Tomasini, Martin Dunbar, David Hoffman, Apurvasena Parikh, Vincent Blot, D. Ross Camidge	1
7	P2.31-05 Determining Lines of Therapy in Patients with Metastatic Non-Small Cell Lung Cancer Using Real-World Data 2023 ·Journal of Thoracic Oncology ·(unknown), Lova Sun, Joshua E. Reuss, (unknown), Geoffrey Liu, (unknown), Stephen V. Liu, (unknown), Tejas Patil, Jorge J. Nieva, (unknown), Kristen A. Marrone, Vincent K. Lam, William Schwartzman, (unknown), Keith L. Miller, D. Ross Camidge, Charu Aggarwal, Wei‐Ting Hwang, Melina E. Marmarelis	0
8	Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non–Small Cell Lung Carcinoma 2021 ·Clinical Cancer Research ·D. Ross Camidge, Daniel Morgensztern, Rebecca S. Heist, Minal Barve, Everett E. Vokes, Jonathan W. Goldman, David S. Hong, Todd M. Bauer, John H. Strickler, Eric Angevin, Monica Motwani, Apurvasena Parikh, Zhaowen Sun, Bruce Allen Bach, Jun Wu, Philip Komarnitsky, Karen Kelly	60
9	Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903) 2020 ·Clinical Cancer Research ·Erin M. Bertino, Ryan D. Gentzler, (unknown), Jill Kolesar, Alona Muzikansky, Eric B. Haura, Zofia Piotrowska, D. Ross Camidge, Thomas E. Stinchcombe, (unknown), Jyoti Malhotra, Liza C. Villaruz, Cloud P. Paweletz, Christie J. Lau, Lynette M. Sholl, Naoko Takebe, Jeffrey A. Moscow, Geoffrey I. Shapiro, Pasi A. Jänne, Geoffrey R. Oxnard	31
10	Resistance Mechanisms to Targeted Therapies in ROS1 + and ALK + Non–small Cell Lung Cancer 2018 ·Clinical Cancer Research ·Caroline E. McCoach, Anh T. Le, Katherine Gowan, Kenneth A. Jones, Laura Schubert, Andrea E. Doak, Adriana Estrada‐Bernal, (unknown), Daniel T. Merrick, Paul A. Bunn, (unknown), Rafał Dziadziuszko, Marileila Varella‐Garcia, Dara L. Aisner, D. Ross Camidge, Robert C. Doebele	179
11	A Phase I Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors 2018 ·Clinical Cancer Research ·Florence Atrafi, Harry J.M. Groen, Lauren A. Byers, Elena Garralda, Martijn P. Lolkema, Randeep Sangha, Santiago Viteri, Young Kwang Chae, D. Ross Camidge, Nashat Gabrail, Beibei Hu, Tian Tian, Silpa Nuthalapati, (unknown), Lei He, Philip Komarnitsky, Antonio Calles	38
12	Therapy of Advanced Non–Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan 2017 ·Journal of Clinical Oncology ·Rebecca S. Heist, Michael J. Guarino, Gregory A. Masters, W. Thomas Purcell, Alexander Starodub, Leora Horn, Ronald Scheff, Aditya Bardia, Wells A. Messersmith, Jordan Berlin, Allyson J. Ocean, Serengulam V. Govindan, Pius Maliakal, Boyd Mudenda, William A. Wegener, Robert M. Sharkey, David M. Goldenberg, D. Ross Camidge	139
13	FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies 2014 ·Clinical Cancer Research ·Murry W. Wynes, Trista K. Hinz, Dexiang Gao, Michael L. Martini, Lindsay A. Marek, Kathryn E. Ware, (unknown), Diana Böhm, Sven Perner, Barbara A. Helfrich, Rafał Dziadziuszko, Jacek Jassem, Szymon Wojtylak, Aleksandra Sejda, Joseph M. Gozgit, Paul A. Bunn, D. Ross Camidge, Aik Choon Tan, Fred R. Hirsch, Lynn E. Heasley	125
14	Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor–Resistant EGFR -Mutant Lung Cancer with and without T790M Mutations 2014 ·Cancer Discovery ·Yelena Y. Janjigian, Egbert F. Smit, Harry J.M. Groen, Leora Horn, Scott Gettinger, D. Ross Camidge, Gregory J. Riely, Bushi Wang, Yali Fu, Vikram K. Chand, Vincent A. Miller, William Pao	295
15	Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung Cancer 2013 ·Cancer Discovery ·Jim Sang, Jaime Acquaviva, Julie C. Friedland, Donald L. Smith, Manuel Sequeira, Chaohua Zhang, Qin Jiang, Liquan Xue, Christine M. Lovly, (unknown), Alice T. Shaw, Robert C. Doebele, Suqin He, Richard C. Bates, D. Ross Camidge, Stephan W. Morris, Iman El‐Hariry, David A. Proia	174
16	Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer breakdown → 2012 ·Clinical Cancer Research ·Robert C. Doebele, Amanda Pilling, Dara L. Aisner, Tatiana G. Kutateladze, Anh T. Le, Andrew Weickhardt, Kimi Kondo, Derek J. Linderman, Lynn E. Heasley, Wilbur A. Franklin, Marileila Varella‐Garcia, D. Ross Camidge	820
17	Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer 2012 ·Clinical Cancer Research ·Kurtis D. Davies, Anh T. Le, Mariana F. Theodoro, Margaret C. Skokan, Dara L. Aisner, Eamon M. Berge, Luigi Terracciano, Federico Cappuzzo, Matteo Incarbone, Massimo Roncalli, Marco Alloisio, Armando Santoro, D. Ross Camidge, Marileila Varella‐Garcia, Robert C. Doebele	330
18	Safety, Pharmacokinetic, and Pharmacodynamic Phase I Dose-Escalation Trial of PF-00562271, an Inhibitor of Focal Adhesion Kinase, in Advanced Solid Tumors 2012 ·Journal of Clinical Oncology ·Jeffrey R. Infante, D. Ross Camidge, Linda Mileshkin, Eric X. Chen, Rodney J. Hicks, Danny Rischin, Howard Fingert, Kristen J. Pierce, Huiping Xu, W. Gregory Roberts, S. Martin Shreeve, Howard A. Burris, Lillian L. Siu	195
19	Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors 2011 ·Clinical Cancer Research ·Pasi A. Jänne, David S. Boss, D. Ross Camidge, Carolyn D. Britten, Jeffrey A. Engelman, Edward B. Garon, Feng Guo, Steven Wong, Jane Liang, Stephen P. Letrent, Robert Millham, Ian Taylor, S. Gail Eckhardt, Jan H.M. Schellens	149
20	The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer 2010 ·Clinical Cancer Research ·Udai Banerji, D. Ross Camidge, Henk M.W. Verheul, Roshan Agarwal, Debashis Sarker, Stan B. Kaye, Ingrid M.E. Desar, Johanna N.H. Timmer-Bonte, Sabine Eckhardt, Karl D. Lewis, Kathryn H. Brown, Mireille Cantarini, Clive Morris, (unknown), Paul D. Smith, Carla M.L. van Herpen	176

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact